Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns

The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track ...
Managed Healthcare Executive

Antifibrotic therapy equally effective in familial and sporadic IPF

Antifibrotic therapy shows similar efficacy in familial and sporadic IPF, with no significant differences in survival or acute exacerbations. Because familial idiopathic pulmonary fibrosis is ...
The Manila Times

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Pl…

AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin ...
Medical Dialogues

Sun Pharma Launches UNLOXCYT for Advanced Skin Cancer in US

Sun Pharmaceutical Industries Limited has announced that UNLOXCYT (cosibelimab-ipdl) is now available in the United States ...
The Manila Times

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid ...

REZENOPY™ received approval from the U.S. Food and Drug Administration (the "FDA”) on April 19, 2024. The newly issued patent is eligible for listing in the FDA’s Orange Book and, if listed, may ...
Medscape

Radiation-Cancer Drug Combo Shows Low Risk for Adverse Events

Metastasis-directed stereotactic radiotherapy alongside biological cancer therapy appears safe, new data show.